Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
StemCell InstituteTSE:7096 -2.40%69 Buyback Yield % is 2.24 as of Jul. 22, 2026, which is 229% above its 10-year median of 0.68. GuruFocus rates TSE:7096 with a GF Score™ of 69/100 and a GF Value™ of 円1,818.55 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 740 Biotechnology companies, StemCell Institute ranks better than 96.76% on this metric.
Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.
StemCell Institute Buyback Yield % Historical Data
* Premium members only.
The historical data trend for StemCell Institute's Buyback Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:7096 vs VRTX, REGN, ALNY: Buyback Yield % Comparison
For the Biotechnology subindustry, StemCell Institute's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
StemCell Institute Buyback Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, StemCell Institute's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where StemCell Institute's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
StemCell Institute (TSE:7096) has a Buyback Yield % of 2.24 as of Jul. 22, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on StemCell Institute and its competitors. This is 229% above median its historical median of 0.68. According to the industry distribution chart, StemCell Institute ranks #24 out of 740 companies in the Biotechnology industry, placing it in the top 3.2%.
Is StemCell Institute's Buyback Yield % too high?
StemCell Institute's current Buyback Yield % of 2.24 is 229% above median its 10-year median of 0.68. Based on the distribution chart, StemCell Institute ranks #24 out of 740 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, StemCell Institute has a GF Score™ of 69/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does StemCell Institute's Buyback Yield % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, StemCell Institute ranks #24 out of 740 companies for Buyback Yield %. This places StemCell Institute in the top 3% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Biotechnology company?
A good Buyback Yield % depends on the Biotechnology industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on StemCell Institute and its competitors. StemCell Institute's current Buyback Yield % is 2.24, which is 229% above median its own 10-year median of 0.68. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is StemCell Institute stock overvalued right now?
Based on GuruFocus' analysis, StemCell Institute (TSE:7096) is currently considered Possible Value Trap. The stock's GF Value™ is 円1,818.55, compared to a current price of 円731.00 — trading 59.8% below its estimated fair value. The current Buyback Yield % is 2.24, which is 229% above median its 10-year median of 0.68. StemCell Institute's overall GF Score™ is 69/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For StemCell Institute (TSE:7096), the current Buyback Yield % is 2.24 as of Jul. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is StemCell Institute (TSE:7096) Overvalued in 2026?
Based on GuruFocus' analysis, StemCell Institute stock appears to be undervalued.
The current stock price of 円731.00 is trading 59.8% below its estimated GF Value™ of 円1,818.55.
GuruFocus considers StemCell Institute to be Possible Value Trap.
Key valuation signals for TSE:7096:
Buyback Yield %: 2.24 (229% above median its 10-year median of 0.68)
GF Value™: 円1,818.55 vs. price of 円731.00 (59.8% below fair value)
No single metric tells the full story. See the TSE:7096 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
StemCell Institute is engaged in the Cell bank business that separates and stores cord blood for regenerative medicine. Cord blood is the baby's blood contained in the umbilical cord and placenta that connects the mother and baby. In its umbilical cord blood storage business, upon receiving notification from customers who have contracted, umbilical cord blood collected at obstetric facilities throughout Japan is collected, transported to the company's cell processing center within 48 hours, and it provides a service to store cells at ultra-low temperature after separating cells from blood. The Company operates in a single segment, the cell bank business sales consist of three components: technical fees, storage fees, and other fees.
69GF Score
Get the complete analysis for TSE:7096
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:7096 has been successfully added to your 
